dalteparin has been researched along with Central Retinal Edema, Cystoid in 2 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonischemic CRVO with cystoid macular edema was diagnosed and an intravitreal injection of ranibizumab was performed." | 5.72 | Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report. ( Biskup, M; Kal, M; Krupińska, J; Odrobina, D; Płatkowska-Adamska, B, 2022) |
| "Nonischemic CRVO with cystoid macular edema was diagnosed and an intravitreal injection of ranibizumab was performed." | 1.72 | Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report. ( Biskup, M; Kal, M; Krupińska, J; Odrobina, D; Płatkowska-Adamska, B, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Płatkowska-Adamska, B | 1 |
| Kal, M | 1 |
| Krupińska, J | 1 |
| Biskup, M | 1 |
| Odrobina, D | 1 |
| Dragoni, F | 1 |
| Kaarniranta, K | 1 |
2 other studies available for dalteparin and Central Retinal Edema, Cystoid
| Article | Year |
|---|---|
Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report.
Topics: Adult; Angiogenesis Inhibitors; COVID-19; COVID-19 Serotherapy; Enoxaparin; Glucocorticoids; Humans; | 2022 |
Individual benefits of enoxaparin treatment in branch vein occlusion.
Topics: Aged; Enoxaparin; Fibrinolytic Agents; Humans; Injections, Subcutaneous; Macular Edema; Male; Middle | 2018 |